Clinical trial Recruiting at 1 site Observational Women only

Examining the biological features of early breast cancer in Pakistani women

Official title: Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population

Run by Liaquat University of Medical & Health Sciences · NCT06830590 · Data updated 2026-11-12

This study looks at the unique biological features of early breast cancer in Pakistani women to better understand the disease.

More Breast Cancer trials

Quick facts

Study typeObservational
SexWomen only
Enrollment300 (estimated)
SponsorLiaquat University of Medical & Health Sciences
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Jamshoro)
StatusRecruiting
StartedFebruary 1, 2016
Main results expectedDecember 30, 2025
Study endsDecember 31, 2025
Registry record updatedAugust 13, 2025
Trial IDNCT06830590 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are women diagnosed with early operable primary breast cancer who have not received any neoadjuvant therapy.

Probably not a fit

Patients who have undergone pre-operative chemotherapy or radiotherapy will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on the molecular characterization of early operable primary breast cancer specifically within the Pakistani population. It aims to analyze the biological characteristics of breast cancer using immunohistochemistry (IHC) techniques. The study will involve women who have a confirmed diagnosis of breast cancer and have not undergone any pre-operative chemotherapy or radiotherapy, ensuring the collection of high-quality tumor samples for analysis.

Why it matters

Potential benefit: If successful, this study could enhance the understanding of breast cancer biology in Pakistani women, leading to improved treatment strategies.

How similar studies have gone: While similar studies have been conducted in other populations, this specific focus on the Pakistani population represents a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Women with confirmed diagnosis of breast cancer without history of taking neoadjuvant therapy Good quality tumour samples available for IHC

Exclusion Criteria:

* patients received pre-operative chemotherapy or radiotherapy

Where it's running

  • Binafsha M Syed
    Jamshoro, Pakistan
    Recruiting

Study contacts

  • Principal investigator: Binafsha Manzoor M Syed, MBBS, PhD — Liaquat University of Medical & Health Sciences, Jamshoro
  • Study coordinator: Binafsha Manzoor M Syed, MBBS, PhD
  • Email: Binafsha.syed@lumhs.edu.pk
  • Phone: +923332749201

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.